Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP

See results from clinical trials with Trulicity when assessed for A1C reduction, weight change and CV risk reduction.

fig3.jpg

Nutrients, Free Full-Text

Frontiers Changes in body weight and cardiovascular risk factors in a Chinese population with type 2 diabetes mellitus: a longitudinal study

Frontiers Changes in body weight and cardiovascular risk factors in a Chinese population with type 2 diabetes mellitus: a longitudinal study

Diabetes Canada Clinical Practice Guidelines

Survey to Specify SGLT2 Inhibitor Choice in T2DM Management, Ghosal

Glucose-lowering therapy in patients undergoing percutaneous coronary intervention

Diabetes North West London Diabetes Clinical Guidelines, PDF, Dieting

T2DM – NWL – Clinical Pathways

Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus

Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review

Research_Review_Special_Report_2023_Update_of_NZSSD_Type_2_Guidelines by WBOP PHO - Issuu

Glucophage® Benefits and Efficacy

Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP